Global Gingivitis Treatment Market - 2023-2030

Global Gingivitis Treatment Market - 2023-2030

Global Gingivitis Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.

Gingivitis is an inflammatory condition of the gingival tissue, most commonly caused by bacterial infection. Unlike periodontitis, there is no attachment loss and therefore no migration of the junctional epithelium. The condition is restricted to the soft-tissue area of the gingival epithelium and connective tissue. Among all the periodontal diseases, gingivitis is considered to be the commonest.

Gingivitis is caused by microbial plaque deposits located in or close to the gingival sulcus. The microorganisms more strongly associated with the etiology of gingivitis include species of Streptococcus, Fusobacterium, Actinomyces, Veillonella, and Treponema. Bacteroides, Capnocytophaga, and Eikenella are also potentially linked to the etiology of the disease.

Market Dynamics: Drivers and Restraints

Rise in awareness and improved management

In addition, increasing disposable incomes and growing awareness of the importance of oral health are driving demand for high-quality oral care products, including those used for gingivitis treatment. This has led to the introduction of new products and technologies in the market, including innovative toothpaste formulations, mouthwashes, and advanced dental instruments.

For instance, in May 2022, Treat your Gums was the slogan for Gum Health Day 2022, a worldwide awareness campaign organised by the European Federation of Periodontology (EFP). The event aims to inform the public of the detrimental effects of gum diseases – gingivitis, periodontitis, peri-implant mucositis, and peri-implantitis on both oral and overall health. The campaign calls for the prevention, early detection, and where necessary effective treatment of gum diseases.

Furthermore, a rise in the prevalence of gingivitis, a rise in advancements in treatment options, collaborations and investments by key players and others will further drive the market to grow during the forecast period.

Market Dynamics: Restraint

Chronic gingiva inflammation is linked to systemic conditions like diabetes, stroke, rheumatoid arthritis, and coronary artery disease. The most common complication is gingivitis, which leads to tooth loss. Anti-gingivitis agents can cause mouth irritation, inflammation, dry mouth, and unusual tastes, with overuse potentially causing chemical burns.

Segment Analysis

The global gingivitis treatment is segmented based on treatment type, sales channel and region.

The non-surgical treatment from the treatment type segment accounted for approximately 41.2% of the market share

The non-surgical segment from the treatment type segment accounted for 41.2% and it is expected to dominate during the forecast period. Non-surgical medical procedures are used to diagnose, measure, monitor or treat problems such as diseases or injuries that don't require surgery. Owing to the non-surgical treatment are minimally invasive, cost-effective, patient-centric approach will drive this segment during the forecast period.

For instance, in April 2022, The University of Texas Health Science Center at San Antonio (UT Health San Antonio) received a four-year award of $2.4m from the US National Institutes of Health (NIH) to study the usage of antibiotics for periodontal disease, commonly called gum disease.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to a growing awareness of the importance of oral health in North America, significant technological advances in gingivitis treatment products, including new toothpaste formulations, advanced dental instruments, and innovative oral care products. Dental insurance is widely available in North America, which makes it easier for people to access gingivitis treatment products and services, novel formulation launches and others.

In July 2022, Pendopharm, a division of Pharmascience Inc., is pleased to introduce PrPERICHLOR WITHOUT ALCOHOL, a new alcohol-free formulation of its gingivitis mouthwash.PrPERICHLOR WITHOUT ALCOHOL is indicated for use as part of a professional program for the treatment of moderate to severe gingivitis, and for management of associated gingival bleeding and inflammation between dental visits.

COVID-19 Impact Analysis

The COVID-19 pandemic led to reduced opening hours and the closure of dental practices, except in the case of emergency procedures. This has limited people’s ability to access routine care. Also, COVID-19 causes organ failure, systemic diseases, and poor oral health, including periodontal disease. The cytokine storm, induced by excessive proinflammatory cytokines, leads to tissue damage.

Common risk factors include obesity, diabetes, cardiovascular disease, age, and smoking. Symptoms of COVID-19 infection include ulcers, erosions, white-red plaques, post-inflammatory pigmentation, petechia, erythema multiforme-like lesions, and necrotizing periodontal disease, with gingiva being a common site of involvement.

Competitive Landscape

The major global players in the gingivitis treatment market include Citron Pharma, Pfizer plc, Novartis AG, Wellona Pharma, Medtronic, Aspen Pharma, Harfins Instruments, AsaDental, Advil, Ora Pharma and among others.

Key Developments

 In May 2023, Bausch Health Companies Inc. and its oral health care business, OraPharma, stated its collaboration with World Series Champion, Alex Rodriguez, to launch a national awareness campaign about the prevalence and impact of gum disease. The campaign launch is timed to Oral Health Month recognized throughout June and features Alex as a patient ambassador.

 In January 2023, Ashland launched saffragyl, a biofunctional that transforms oral health into a daily beauty regimen by proposing a natural, safe, and effective bioactive to take care of the biology of the gingiva. It offers a preventive answer to gums prone to gingivitis and is microbiome-friendly, gum-friendly and can be used daily.

 In October 2022, it was stated that a rapid test for gum disease was being developed by researchers at the University of Birmingham. The probe, designed for use in point-of-care settings such as dental surgeries or pharmacies, is expected to aid in the early detection of heart or lung disease, type 2 diabetes, and rheumatoid arthritis.

Why Purchase the Report?
• To visualize the global gingivitis treatment market segmentation-based type, treatment type, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of gingivitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global gingivitis treatment market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies